Skip to content
Disclosery

Opaleye Management Inc.

Follow

13F filer, CIK 1595855, BOSTON, MA

Opaleye Management Inc. reported $1,104,182,260 across 58 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 64.76% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-26-001803

Period
2026-06-30
Reported value
$1.1B
Holdings
58
Top 10 weight
64.76%
New
13
Sold out
9

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IRONadded+434,000$31.7M
IMMXnew+2,345,000$24.2M
MGTXadded+1,426,741$19.3M
GLUEnew+745,000$18M
REPLnew+1,384,993$15.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CATXexited-4,675,000-$19.5M
HROWreduced-432,230-$18.4M
LQDAreduced-97,500-$7.77M
SNWVreduced-675,127-$6.75M
JBIOreduced-282,608-$6.28M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001420506-26-001803, largest first. % of portfolio is the value over $1,104,182,260, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LQDALIQUIDIA CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,698,142 shares; 2024Q4: 1,698,142 shares; 2025Q1: 2,260,000 shares; 2025Q2: 2,475,000 shares; 2025Q3: 2,615,000 shares; 2025Q4: 2,435,000 shares; 2026Q1: 2,545,000 shares; 2026Q2: 2,447,500 shares 2,447,500$195M17.67%-97,500Timeline
ETONETON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,780,000 shares; 2024Q4: 2,852,070 shares; 2025Q1: 2,852,070 shares; 2025Q2: 2,860,000 shares; 2025Q3: 2,860,000 shares; 2025Q4: 2,860,000 shares; 2026Q1: 2,860,000 shares; 2026Q2: 2,860,000 shares 2,860,000$104M9.38%0Timeline
HROWHARROW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,990,000 shares; 2024Q4: 3,990,000 shares; 2025Q1: 3,955,000 shares; 2025Q2: 3,905,000 shares; 2025Q3: 3,905,000 shares; 2025Q4: 3,905,000 shares; 2026Q1: 2,832,230 shares; 2026Q2: 2,400,000 shares 2,400,000$102M9.23%-432,230Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 85,000 shares; 2025Q2: 186,418 shares; 2025Q3: 193,773 shares; 2025Q4: 200,000 shares; 2026Q1: 421,000 shares; 2026Q2: 855,000 shares 855,000$62.5M5.66%+434,000Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 404,100 shares; 2024Q4: 220,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 268,423 shares; 2026Q1: 1,430,000 shares; 2026Q2: 1,439,996 shares 1,439,996$53M4.8%+9,996Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 363,257 shares; 2025Q4: 388,257 shares; 2026Q1: 390,000 shares; 2026Q2: 390,000 shares 390,000$51.8M4.69%0Timeline
MGTXMEIRAGTX HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 390,844 shares; 2026Q1: 2,123,259 shares; 2026Q2: 3,550,000 shares 3,550,000$48M4.34%+1,426,741Timeline
SLGLSOL-GEL TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 204,835 shares; 2025Q4: 453,739 shares; 2026Q1: 500,000 shares; 2026Q2: 500,000 shares 500,000$37.1M3.36%0Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 466,563 shares; 2024Q4: 465,000 shares; 2025Q1: 465,000 shares; 2025Q2: 903,442 shares; 2025Q3: 903,442 shares; 2025Q4: 6,287,156 shares; 2026Q1: 6,300,000 shares; 2026Q2: 6,300,000 shares 6,300,000$32.8M2.97%0Timeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,280,000 shares; 2024Q4: 2,260,000 shares; 2025Q1: 535,000 shares; 2025Q2: 535,000 shares; 2025Q3: 535,000 shares; 2025Q4: 535,000 shares; 2026Q1: 535,000 shares; 2026Q2: 535,000 shares 535,000$29.4M2.66%0Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,345,000 shares 2,345,000$24.2M2.19%newTimeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,178,300 shares; 2026Q1: 1,312,615 shares; 2026Q2: 1,319,351 shares 1,319,351$23.7M2.15%+6,736Timeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 25,000 shares; 2025Q1: 300,000 shares; 2025Q2: 562,120 shares; 2025Q3: 682,017 shares; 2025Q4: 695,000 shares; 2026Q1: 700,000 shares; 2026Q2: 700,000 shares 700,000$22.9M2.07%0Timeline
ACOGALPHA COGNITION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 115,142 shares; 2025Q4: 2,070,784 shares; 2026Q1: 2,561,950 shares; 2026Q2: 2,895,467 shares 2,895,467$20.9M1.89%+333,517Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 522,500 shares; 2024Q4: 480,000 shares; 2025Q1: 395,000 shares; 2025Q2: 490,000 shares; 2025Q3: 500,000 shares; 2025Q4: 500,000 shares; 2026Q1: 500,000 shares; 2026Q2: 500,000 shares 500,000$20.3M1.84%0Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 105,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 100,000 shares; 2026Q2: 100,000 shares 100,000$18.7M1.7%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 745,000 shares 745,000$18M1.63%newTimeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 775,000 shares; 2025Q3: 665,000 shares; 2025Q4: 535,000 shares; 2026Q1: 550,000 shares; 2026Q2: 550,000 shares 550,000$15.5M1.4%0Timeline
CDXSCODEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,770,000 shares; 2024Q4: 8,840,000 shares; 2025Q1: 9,500,000 shares; 2025Q2: 12,600,000 shares; 2025Q3: 12,795,000 shares; 2025Q4: 6,789,738 shares; 2026Q1: 6,785,000 shares; 2026Q2: 6,785,000 shares 6,785,000$15.3M1.39%0Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,384,993 shares 1,384,993$15.3M1.39%newTimeline
XOMAXOMA ROYALTY CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 250,000 shares; 2024Q4: 250,000 shares; 2025Q1: 253,043 shares; 2025Q2: 255,087 shares; 2025Q3: 255,087 shares; 2025Q4: 292,590 shares; 2026Q1: 300,000 shares; 2026Q2: 338,374 shares 338,374$14.4M1.3%+38,374Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 250,000 shares; 2025Q2: 239,319 shares; 2025Q3: 253,000 shares; 2025Q4: 260,000 shares; 2026Q1: 260,000 shares; 2026Q2: 260,000 shares 260,000$14.4M1.3%0Timeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 500,000 shares; 2024Q4: 500,000 shares; 2025Q1: 490,000 shares; 2025Q2: 475,000 shares; 2025Q3: 461,700 shares; 2025Q4: 330,000 shares; 2026Q1: 123,000 shares; 2026Q2: 122,500 shares 122,500$13.6M1.23%-500Timeline
EDITEDITAS MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,926,997 shares; 2026Q2: 3,861,930 shares 3,861,930$12.5M1.13%+1,934,933Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 105,000 shares; 2024Q4: 105,000 shares; 2025Q1: 105,000 shares; 2025Q2: 105,000 shares; 2025Q3: 105,000 shares; 2025Q4: 105,000 shares; 2026Q1: 100,000 shares; 2026Q2: 100,000 shares 100,000$12.3M1.11%0Timeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 808,882 shares; 2025Q4: 900,000 shares; 2026Q1: 1,380,000 shares; 2026Q2: 3,863,800 shares 3,863,800$12M1.09%+2,483,800Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 213,363 shares; 2026Q1: 1,256,228 shares; 2026Q2: 931,000 shares 931,000$11.9M1.07%-325,228Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,600,000 shares; 2025Q4: 2,600,000 shares; 2026Q1: 2,331,761 shares; 2026Q2: 1,714,451 shares 1,714,451$9.79M0.89%-617,310Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,800,000 shares 1,800,000$6.88M0.62%newTimeline
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 967,000 shares; 2024Q4: 1,767,500 shares; 2025Q1: 1,985,000 shares; 2025Q2: 1,924,300 shares; 2025Q3: 316,550 shares; 2025Q4: 1,400,906 shares; 2026Q1: 1,412,656 shares; 2026Q2: 1,412,656 shares 1,412,656$6.85M0.62%0Timeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 480,000 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 935,000 shares; 2026Q1: 935,000 shares; 2026Q2: 935,000 shares 935,000$6.47M0.59%0Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 5,025,000 shares; 2024Q4: 4,342,500 shares; 2025Q1: 1,595,000 shares; 2025Q2: 1,595,000 shares; 2025Q3: 1,595,000 shares; 2025Q4: 1,595,000 shares; 2026Q1: 600,000 shares; 2026Q2: 600,000 shares 600,000$5.89M0.53%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,567,990 shares; 2024Q4: 2,317,500 shares; 2025Q1: 795,000 shares; 2025Q2: 390,000 shares; 2025Q3: 390,000 shares; 2025Q4: 345,100 shares; 2026Q1: 345,100 shares; 2026Q2: 310,000 shares 310,000$5.78M0.52%-35,100Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 53,282 shares; 2026Q2: 700,000 shares 700,000$5.33M0.48%+646,718Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 79,097 shares; 2026Q2: 344,025 shares 344,025$4.83M0.44%+264,928Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,175,000 shares; 2025Q2: 1,220,000 shares; 2025Q3: 1,100,000 shares; 2025Q4: 1,120,000 shares; 2026Q1: 1,120,000 shares; 2026Q2: 1,125,000 shares 1,125,000$4.62M0.42%+5,000Timeline
FDMT4D MOLECULAR THERAPEUTICS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 112,291 shares; 2026Q2: 334,437 shares 334,437$4.45M0.4%+222,146Timeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 245,000 shares; 2026Q2: 250,000 shares 250,000$4.23M0.38%+5,000Timeline
VYGRVOYAGER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,196,904 shares; 2026Q1: 1,150,000 shares; 2026Q2: 1,185,000 shares 1,185,000$4.15M0.38%+35,000Timeline
BDSXBIODESIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 238,047 shares; 2026Q2: 180,000 shares 180,000$4.06M0.37%-58,047Timeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 955,000 shares; 2026Q1: 955,000 shares; 2026Q2: 1,000,000 shares 1,000,000$3.42M0.31%+45,000Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 427,608 shares; 2026Q1: 427,608 shares; 2026Q2: 145,000 shares 145,000$3.22M0.29%-282,608Timeline
SNWVSANUWAVE HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 972,002 shares; 2025Q2: 980,000 shares; 2025Q3: 980,000 shares; 2025Q4: 981,267 shares; 2026Q1: 981,267 shares; 2026Q2: 306,140 shares 306,140$3.06M0.28%-675,127Timeline
FBIOFORTRESS BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,090,000 shares; 2026Q1: 1,042,000 shares; 2026Q2: 890,000 shares 890,000$2.72M0.25%-152,000Timeline
DERMJOURNEY MED CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 69,323 shares; 2025Q2: 95,000 shares; 2025Q3: 971,064 shares; 2025Q4: 975,000 shares; 2026Q1: 960,000 shares; 2026Q2: 350,000 shares 350,000$2.48M0.22%-610,000Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 185,589 shares 185,589$2.01M0.18%newTimeline
INBXINHIBRX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 20,291 shares 20,291$1.92M0.17%newTimeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 75,000 shares; 2026Q1: 125,000 shares; 2026Q2: 125,000 shares 125,000$1.82M0.17%0Timeline
COAGHEMAB THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 47,652 shares 47,652$1.75M0.16%newTimeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 65,000 shares 65,000$1.31M0.12%newTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 163,988 shares; 2025Q2: 266,000 shares; 2025Q3: 410,000 shares; 2025Q4: 410,000 shares; 2026Q1: 94,800 shares; 2026Q2: 17,789 shares 17,789$1.26M0.11%-77,011Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 77,915 shares 77,915$1.16M0.1%newTimeline
AVIRATEA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 179,815 shares; 2026Q1: 322,600 shares; 2026Q2: 235,000 shares 235,000$1.09M0.1%-87,600Timeline
KTTAPASITHEA THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,050,000 shares 2,050,000$1.06M0.1%newTimeline
ADCTADC THERAPEUTICS SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 682,529 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 700,000 shares 700,000$749K0.07%newTimeline
OKYOOKYO PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 375,204 shares 375,204$563K0.05%newTimeline
PTNPALATIN TECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 20,500 shares 20,500$221K0.02%newTimeline
ADGMADAGIO MED HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 110,571 shares; 2024Q4: 110,571 shares; 2025Q1: 110,571 shares; 2025Q2: 110,571 shares; 2025Q3: 110,571 shares; 2025Q4: 18,444 shares; 2026Q1: 18,444 shares; 2026Q2: 18,444 shares 18,444$13.4K<0.01%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CATXPERSPECTIVE THERAPEUTICS INC4,675,000$19.5Mshares
ASRTASSERTIO HOLDINGS INC265,707$5.06Mshares
STROSUTRO BIOPHARMA INC190,671$4.75Mshares
TECXTECTONIC THERAPEUTIC INC123,000$3.8Mshares
RIGLRIGEL PHARMACEUTICALS INC70,000$1.89Mshares
NXTCNEXTCURE INC141,181$1.51Mshares
PERSPECTIVE THERAPEUTICS INCPERSPECTIVE THERAPEUTICS INC200,000$834Kshares
PLXPROTALIX BIOTHERAPEUTICS INC340,000$738Kshares
LBRXLB PHARMACEUTICALS INC14,506$358Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-26-001803 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
Form 4 0001493152-26-045809 Grace Therapeutics, Inc.2026-10-05
Form 4 0001493152-26-045511 Alpha Cognition Inc.2026-10-02
Form 4 0001493152-26-045358 Grace Therapeutics, Inc.2026-10-01
Form 4/A 0001493152-26-045347 Grace Therapeutics, Inc.2026-10-01
Form 4 0001493152-26-044690 Alpha Cognition Inc.2026-09-28
13F-HR 0001420506-26-001803 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001420506-26-001151 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR/A 0001493152-26-016299 Quarter ended 2025-12-312026-04-13acceptance time not in the bulk data set
13F-HR 0001493152-26-007085 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001493152-25-023429 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR/A 0001641172-25-024301 Quarter ended 2025-06-302025-08-15acceptance time not in the bulk data set
13F-HR 0001641172-25-023977 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001641172-25-010914 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001493152-25-006852 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001493152-24-045811 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001493152-24-032150 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR/A 0001493152-24-021780 Quarter ended 2024-03-312024-05-29acceptance time not in the bulk data set
13F-HR 0001493152-24-019869 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001493152-24-006653 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001493152-23-041364 Quarter ended 2023-09-302023-11-15acceptance time not in the bulk data set
13F-HR 0001493152-23-028636 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001493152-23-016769 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001493152-23-004277 Quarter ended 2022-12-312023-02-10acceptance time not in the bulk data set
13F-HR 0001493152-22-032068 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001493152-22-022856 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001493152-22-013764 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001493152-22-004434 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001493152-21-028799 Quarter ended 2021-09-302021-11-16acceptance time not in the bulk data set
13F-HR 0001493152-21-020260 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0001493152-21-012017 Quarter ended 2021-03-312021-05-18acceptance time not in the bulk data set
13F-HR 0001493152-21-003697 Quarter ended 2020-12-312021-02-12acceptance time not in the bulk data set
13F-HR 0001493152-20-021694 Quarter ended 2020-09-302020-11-16acceptance time not in the bulk data set
13F-HR 0001493152-20-015902 Quarter ended 2020-06-302020-08-14acceptance time not in the bulk data set
13F-HR 0001493152-20-009140 Quarter ended 2020-03-312020-05-15acceptance time not in the bulk data set
13F-HR 0001493152-20-002529 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0001493152-19-017503 Quarter ended 2019-09-302019-11-14acceptance time not in the bulk data set
13F-HR 0001493152-19-012567 Quarter ended 2019-06-302019-08-14acceptance time not in the bulk data set
13F-HR 0001493152-19-007425 Quarter ended 2019-03-312019-05-15acceptance time not in the bulk data set
13F-HR 0001493152-19-002114 Quarter ended 2018-12-312019-02-14acceptance time not in the bulk data set
13F-HR 0001493152-18-016123 Quarter ended 2018-09-302018-11-14acceptance time not in the bulk data set
13F-HR 0001493152-18-011830 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR 0001493152-18-006822 Quarter ended 2018-03-312018-05-14acceptance time not in the bulk data set
13F-HR 0001493152-18-001743 Quarter ended 2017-12-312018-02-09acceptance time not in the bulk data set
13F-HR 0001493152-17-013210 Quarter ended 2017-09-302017-11-14acceptance time not in the bulk data set
13F-HR 0001493152-17-009239 Quarter ended 2017-06-302017-08-14acceptance time not in the bulk data set
13F-HR 0001493152-17-005196 Quarter ended 2017-03-312017-05-15acceptance time not in the bulk data set
13F-HR 0001144204-17-010166 Quarter ended 2016-12-312017-02-21acceptance time not in the bulk data set
13F-HR 0001546927-16-000542 Quarter ended 2016-09-302016-11-14acceptance time not in the bulk data set
13F-HR 0001546927-16-000512 Quarter ended 2016-06-302016-08-12acceptance time not in the bulk data set
13F-HR/A 0001546927-16-000514 Quarter ended 2016-06-302016-08-12acceptance time not in the bulk data set
13F-HR/A 0001546927-16-000499 Quarter ended 2016-03-312016-05-27acceptance time not in the bulk data set
13F-HR 0001546927-16-000493 Quarter ended 2016-03-312016-05-16acceptance time not in the bulk data set
13F-HR 0001546927-16-000408 Quarter ended 2015-12-312016-02-12acceptance time not in the bulk data set
13F-HR 0001546927-15-000281 Quarter ended 2015-09-302015-11-13acceptance time not in the bulk data set
13F-HR 0001546927-15-000231 Quarter ended 2015-06-302015-08-14acceptance time not in the bulk data set
13F-HR 0001546927-15-000149 Quarter ended 2015-03-312015-05-15acceptance time not in the bulk data set
13F-HR 0001546927-15-000070 Quarter ended 2014-12-312015-02-13acceptance time not in the bulk data set
13F-HR 0001546927-14-000196 Quarter ended 2014-09-302014-11-14acceptance time not in the bulk data set
13F-HR 0001546927-14-000159 Quarter ended 2014-06-302014-08-14acceptance time not in the bulk data set
13F-HR 0001546927-14-000115 Quarter ended 2014-03-312014-05-15acceptance time not in the bulk data set
13F-HR 0001546927-14-000060 Quarter ended 2013-12-312014-02-14acceptance time not in the bulk data set